What question did this study set out to answer?

To evaluate how immune-related adverse events affect treatment response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer patients.

February 25, 2026Open Access

Impact of immune-related adverse events on response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer: a single-institution retrospective study

Puntos clave

To evaluate how immune-related adverse events affect treatment response to neoadjuvant chemoimmunotherapy in triple-negative breast cancer patients.
Conducted a retrospective study at a single institution
Analyzed the impacts of immune-related adverse events on treatment outcomes
Examined variations in response based on age and race
Immune-related adverse events may indicate better treatment responses
Racial and age differences in treatment response were observed
Findings underscore the need for inclusion of diverse patient populations in immunotherapy research

Resumen

IrAEs may serve as a surrogate for treatment response to neoadjuvant chemoimmunotherapy in early TNBC. Additionally, racial and age-based differences in treatment response suggest underlying immunologic or biologic variation. These findings highlight the importance of diverse cohort representation in immunotherapy studies and warrant validation in prospective trials.

Me gusta

Guardar

Ver artículo completo

Cite This Study

Sterpi et al. (Mon,) studied this question.

synapsesocial.com/papers/699e911bf5123be5ed04e6eb https://doi.org/https://doi.org/10.1007/s10549-026-07930-8

Me gusta

Guardar

Ver artículo completo